Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Post by EEnsighton Dec 04, 2016 1:51pm
441 Views
Post# 25552319

Fully Diluted Share Count

Fully Diluted Share CountWhat is the expected fully diluted share count (incl all options, warrants, MeddCan and Mettrum acquisitions).  My guess is when the dust settles by end of 2017 CGC will be at 200 million.  We all need to use a higher share count in our valuations.  Also what sort sort forward looking price earnings ratio or EBIDA multiple would be realistic.  I think we could safely use 20x forward earnings, especially in the first couple years starting with 2018 forecasts.  Once we have that kinda in focus then we can talk abut market share by market segment (Med, Rec) domestic and international.  I think even with 200 million shares we can conservatively value CGC at $35-50/share by 2018 Q2.
Bullboard Posts